ProQR Therapeutics
PRQR
67 hedge funds and large institutions have $333M invested in ProQR Therapeutics in 2021 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 27 increasing their positions, 18 reducing their positions, and 8 closing their positions.
65% more call options, than puts
Call options by funds: $2.1M | Put options by funds: $1.28M
50% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 8
50% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 18
29% more capital invested
Capital invested by funds: $259M → $333M (+$74M)
6% more funds holding
Funds holding: 63 → 67 (+4)
2.11% more ownership
Funds ownership: 60.08% → 62.19% (+2.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$10.8M |
| 2 |
GGHC
Gilder Gagnon Howe & Co
New York
|
+$4.14M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2.99M |
| 4 |
Millennium Management
New York
|
+$2.13M |
| 5 |
JGC
J. Goldman & Co
New York
|
+$1.28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$4.96M |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$4.81M |
| 3 |
SCM
Sio Capital Management
New York
|
-$2.56M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$2.06M |
| 5 |
Morgan Stanley
New York
|
-$1.79M |
PRQR Hedge Fund Activity: Q3 2021 in Review
67 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q3 2021, worth a combined $333M — up 29% from $259M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new PRQR positions and 8 closed out — a net gain of 4 holders — while 27 added to existing stakes and 18 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $10.8M. The largest seller was Jennison Associates, cutting an estimated $4.96M.
- 67 institutional investors held ProQR Therapeutics (PRQR) as of Q3 2021, up from 63 in Q2 2021.
- Funds reported $333M of ProQR Therapeutics stock for Q3 2021, up 29% quarter-over-quarter.
- 12 funds opened new ProQR Therapeutics positions in Q3 2021 and 8 closed out, a net change of +4 holders.
- The largest ProQR Therapeutics buyer in Q3 2021 was Wellington Management Group, an estimated $10.8M added.
- The largest ProQR Therapeutics seller in Q3 2021 was Jennison Associates, an estimated $4.96M sold.
Based on aggregated 13F filings for Q3 2021.